The Latest Articles from Streetwise Reports


Protalix Shares Trade up 70% Upon Release of Phase 3 Fabry Disease Data

  ()
Shares of Protalix Biotherapeutics skyrocketed on much higher than average volume as the firm announced positive 12-month interim data from its BRIDGE Phase 3 open label switch-over study of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. read more >
News Update

Healthcare Tech Firm Signs Five New Clients in Texas

News Update
  ()
The company just landed another five clients in Texas and now plans to build out sales teams in five additional states. read more >

Achillion Pharma Shares Open 75% Higher After Alexion Buyout Offer

  ()
Shares of Achillion Pharmaceuticals traded much higher after the firm reported that it has agreed to be acquired by Alexion Pharmaceuticals for $930 million, or $6.30 per share in cash, along with the potential for an additional $2 per share if certain other specific clinical trial and regulatory milestones are met. read more >

Assembly Biosciences Stock Sizzles Following Phase 2a Announcement and Buy Rating from Mizuho

  ()
Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close. read more >

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

  ()
Shares of Relmada Therapeutics traded wildly after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100200% higher and the stock was halted several times trading due to extreme price volatility. read more >
News Update

Healthcare Company to Use IBM's Watson AI in Telemedicine App

News Update
  ()
The goal is to reduce the time healthcare workers spend on mundane tasks and thereby improve patient care. read more >

Cerecor Shares Rise 13% on Sale of Pediatric Portfolio for $32 Million

  ()
Shares of Cerecor Inc. traded higher after reporting that it will sell its pediatric portfolio to Aytu BioScience for $32 million in a combination cash and stock deal. read more >

Technical Analyst Expects Health Technologies Firm to Break Higher

Contributed Opinion
  ()
Technical analyst Clive Maund outlines the reasons this stock might break higher. read more >

Technical Analyst: As Antibiotic Resistance Rises, So May the Stock of This Livestock Feed Company

Contributed Opinion
  ()
Technical analyst Clive Maund believes this stock could gain traction soon. read more >

Reata Pharma Shares Trading Higher After Reacquiring U.S. and Worldwide Licensing Rights

  ()
Shares of Reata Pharmaceuticals traded 12% higher after the firm announced it had reacquired all licensing rights in the U.S. for bardoxolone methyl and worldwide rights for omaveloxolone and other next-generation Nrf2 activators from AbbVie. read more >

Ra Pharmaceuticals Shares Up 100% Following $2.1 Billion Takeover Bid

  ()
Shares of Ra Pharmaceuticals doubled after the firm announced that it will be acquired by Belgian firm UCB for $48 per share in an all cash deal. read more >

Soliton Shares Rise on Announcement It Will Report Clinical Data at National Dermatology Conference

  ()
Soliton Inc. shares traded 10% higher after advising that later this month it will present the data from clinical trials for its Rapid Acoustic Pulse device used in the treatment of keloid and hypertrophic scars at the American Society for Dermatologic Surgery Annual Meeting. read more >
News Update

Biopharma Completes Enrollment in Phase 2a Plaque Psoriasis Trial

News Update
  ()
Data from this study should be released by the end of this year. read more >
News Update

JV with Moosehead Breweries Readying Cannabis-Infused Beverages for Commercialization

News Update
  ()
Progress has been made in all areas, from testing the product to evaluating distributors. read more >

Coverage Initiated on U.S.-Based Precision Therapy Developer

Research Report
  ()
The key reasons this story is compelling are given in an H.C. Wainwright & Co. report. read more >

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30%

  ()
Akcea Therapeutics' shares rose 30% on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANGPTL3-LRx used in the treatment of patients with cardiovascular and metabolic diseases. read more >
News Update

Healthcare Tech Company Switches to EY Blockchain Platform

News Update
  ()
This will help its customers access the products and tools they need more sustainably. read more >
News Update

Healthcare Tech Firm Expands Patient Base in Texas

News Update
  ()
The company landed five new U.S. facilities as customers. read more >

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

  ()
PDS Biotechnology Corp. shares traded 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection. read more >

Zynex Shares Trade Higher After Reporting a 95% Increase in Q3 Orders

  ()
Non-invasive medical device maker Zynex Inc's. shares traded 12% higher on an overall down market day after the company reported that Q3/19 orders are up 95% over the same period in 2018. read more >

Dova Pharma Shares Rise 38% on Swedish Firm Takeover Offer

  ()
Shares of Dova Pharmaceuticals rose 38% on news that the firm will be acquired by Swedish Orphan Biovitrum. The deal is reportedly valued at $915 million or $29/share. read more >

U.S. Biotech Rolls Out New Brachytherapy Delivery Tool Used for Prostate Cancer

Research Report
  ()
The system, target markets and the marketing campaign for it are discussed in a Dawson James Securities report. read more >

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'

Research Report
  ()
The latest clinical trial results are dissected in a ROTH Capital Partners report. read more >

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study

  ()
Shares of Aravive Inc. traded higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. read more >

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results

  ()
Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint. read more >
Showing Results: 1 to 25 of 157 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts